目的 探究雙石通淋膠囊聯(lián)合羅紅霉素治療IIIA型前列腺炎的臨床效果。方法 選取2020年1月—2020年10月在天津市東麗區(qū)東麗醫(yī)院接受治療的118例IIIA型前列腺炎患者，使用隨機(jī)數(shù)字表的方法分為對(duì)照組和治療組，每組各59例。對(duì)照組飯前口服羅紅霉素緩釋膠囊，1粒/次，1次/d。治療組在對(duì)照組基礎(chǔ)上飯前口服雙石通淋膠囊，4粒/次，3次/d。兩組均連續(xù)治療4周。觀察兩組的臨床療效，比較兩組患者慢性前列腺炎癥狀指數(shù)評(píng)分（NIH-CPSI）、炎癥指標(biāo)及前列腺液γ干擾素（IFN-γ）、轉(zhuǎn)化生長因子β1（TGF-β1）水平。結(jié)果 治療后，治療組患者總有效率為94.9%，顯著高于對(duì)照組的83.1%（P<0.05）。治療后，兩組患者疼痛或不適評(píng)分、排尿癥狀評(píng)分、生活質(zhì)量評(píng)分、NIH-CPSI總評(píng)分均顯著降低（P<0.05）；治療后治療組NIH-CPSI評(píng)分顯著低于對(duì)照組（P<0.05）。治療后，兩組白細(xì)胞（WBC）、C反應(yīng)蛋白（CRP）、白細(xì)胞介素-2（IL-2）水平較較治療前顯著降低（P<0.05）；治療后治療組炎癥指標(biāo)水平顯著低于對(duì)照組（P<0.05）。治療后，兩組患者IFN-γ、TGF-β1水平均顯著降低（P<0.05）；治療后，治療組前列腺液IFN-γ、TGF-β1水平低于對(duì)照組（P<0.05）。結(jié)論 雙石通淋膠囊聯(lián)合羅紅霉素治療IIIA型前列腺炎具有較好的臨床療效，能夠有效改善患者的臨床癥狀，降低炎癥反應(yīng)，且安全性較好，值得臨床推廣。

Objective To explore the therapeutic effect of Shuangshi Tonglin Capsules combined with roxithromycin in treatment of type IIIA prostatitis. Methods A total of 118 patients with type IIIA prostatitis who were treated in Dongli Hospital of Dongli District in Tianjin from January 2020 to October 2020 were selected and divided into control group and treatment group by random number table method, with 59 cases in each group. Patients in the control group were po administered with Roxithromycin Sustained Release Capsules, 1 grain/time, once daily. Patients in the treatment group were po administered with Shuangshi Tonglin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the chronic prostatic inflammation index score (NIH-CPSI), inflammatory indicators, prostatic fluid interferon γ (IFN-γ), transforming growth factor β1 (TGF-β1) levels were compared between two groups. Results After treatment, the total effective rate in the treatment group was 94.9%, which is significantly higher than that in the control group (83.1%) (P < 0.05). After treatment, pain or discomfort score, urination symptom score, life quality score and NIH-CPSI total score in treatment group were significantly decreased (P < 0.05). NIH-CPSI score in treatment group was significantly lower than that in control group (P < 0.05). After treatment, the levels of white blood cell (WBC), C-reactive protein (CRP), and interleukin-2 (IL-2) in two groups were significantly decreased (P < 0.05). After treatment, the levels of inflammatory indicators in treatment group were significantly lower than those in control group (P < 0.05). After treatment, the levels of IFN-γ and TGF-β1 in two two groups were significantly decreased (P < 0.05). After treatment, the levels of IFN-γ and TGF-β1 in prostatic fluid in treatment group were lower than those in control group (P < 0.05). Conclusion Clinical study of Shuangshi Tonglin Capsules combined with roxithromycin has good clinical effect in treatment of type IIIA prostatitis, and can effectively improve the clinical symptoms of patients, reduce the inflammatory response with good safety, which is worthy of clinical promotion.

R983

天津市衛(wèi)生和計(jì)劃生育委員會(huì)科研基金項(xiàng)目（2017KZ059）